drugset
drugset / Trial / NCT01367600

Open-Label Treatment Extension of Protocol MNTX 301

NCT01367600 ↗

Phase 3 Completed 27 enrolled Bausch Health Americas, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.

Timeline

Start
2003-02
Primary completion
2005-02
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylnaltrexone Other / unclassified — Subcutaneous

Indications

No indication recorded.